ARTICLE | Company News
ICER panel split on value of CAR Ts
March 2, 2018 11:42 PM UTC
The Institute for Clinical and Economic Review's California Technology Assessment Forum voted that the value of Kymriah tisagenlecleucel was intermediate, while the panel was mixed on whether the value of Yescarta axicabtagene ciloleucel was intermediate or low.
Seven members voted that the value of Kymriah from Novartis AG (NYSE:NVS; SIX:NOVN) has an intermediate value compared with clofarabine, while 3 voted it had high value. The remaining vote was for low value...
BCIQ Target Profiles